These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 34284462)

  • 1. Low-dose ipilimumab combined with anti-PD-1 immunotherapy in patients with metastatic melanoma following anti-PD-1 treatment failure.
    Klee G; Kurzhals J; Hagelstein V; Zillikens D; Recke A; Langan EA; Terheyden P
    Melanoma Res; 2021 Oct; 31(5):464-471. PubMed ID: 34284462
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study.
    Pires da Silva I; Ahmed T; Reijers ILM; Weppler AM; Betof Warner A; Patrinely JR; Serra-Bellver P; Allayous C; Mangana J; Nguyen K; Zimmer L; Trojaniello C; Stout D; Lyle M; Klein O; Gerard CL; Michielin O; Haydon A; Ascierto PA; Carlino MS; Lebbe C; Lorigan P; Johnson DB; Sandhu S; Lo SN; Blank CU; Menzies AM; Long GV
    Lancet Oncol; 2021 Jun; 22(6):836-847. PubMed ID: 33989557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Anti-Programmed Cell Death 1 Antibody Treatment With Risk of Recurrence of Toxic Effects After Immune-Related Adverse Events of Ipilimumab in Patients With Metastatic Melanoma.
    Brunot A; Grob JJ; Jeudy G; Grange F; Guillot B; Kramkimel N; Mortier L; Le Corre Y; Aubin FF; Mansard S; Lebbé C; Blom A; Montaudie H; Giacchero D; Prey S; Legoupil D; Guyot A; Amini-Adle M; Granel-Brocard F; Meyer N; Dinulescu M; Edeline J; Campillo-Gimenez B; Lesimple T
    JAMA Dermatol; 2020 Sep; 156(9):982-986. PubMed ID: 32667663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of ipilimumab after anti-PD-1 therapy in sequential treatment of metastatic melanoma patients - Real world evidence.
    Cybulska-Stopa B; Rogala P; Czarnecka AM; Ługowska I; Teterycz P; Galus Ł; Rajczykowski M; Dawidowska A; Piejko K; Suwiński R; Mackiewicz J; Rutkowski P
    Adv Med Sci; 2020 Sep; 65(2):316-323. PubMed ID: 32554313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma.
    Pollack MH; Betof A; Dearden H; Rapazzo K; Valentine I; Brohl AS; Ancell KK; Long GV; Menzies AM; Eroglu Z; Johnson DB; Shoushtari AN
    Ann Oncol; 2018 Jan; 29(1):250-255. PubMed ID: 29045547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of BRAF mutation status on clinical outcomes with anti-PD-1 monotherapy versus combination ipilimumab/nivolumab in treatment-naïve advanced stage melanoma.
    Ma VT; Daignault-Newton S; Waninger JJ; Journey S; Chopra Z; Tezel A; Redman BG; Fecher LA; Green MD; Alva AS; Lao CD
    Pigment Cell Melanoma Res; 2021 May; 34(3):629-640. PubMed ID: 33128316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health care utilization and steroid-refractory toxicities from immune checkpoint inhibitors.
    Wang LX; Quach HT; Moodabigil NV; Davis EJ; Sosman JA; Dusetzina SB; Johnson DB
    Cancer; 2020 Jan; 126(2):322-328. PubMed ID: 31580492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab.
    Menzies AM; Johnson DB; Ramanujam S; Atkinson VG; Wong ANM; Park JJ; McQuade JL; Shoushtari AN; Tsai KK; Eroglu Z; Klein O; Hassel JC; Sosman JA; Guminski A; Sullivan RJ; Ribas A; Carlino MS; Davies MA; Sandhu SK; Long GV
    Ann Oncol; 2017 Feb; 28(2):368-376. PubMed ID: 27687304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma.
    Indini A; Di Guardo L; Cimminiello C; Prisciandaro M; Randon G; De Braud F; Del Vecchio M
    J Cancer Res Clin Oncol; 2019 Feb; 145(2):511-521. PubMed ID: 30539281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigation of clinical factors associated with longer overall survival in advanced melanoma patients treated with sequential ipilimumab.
    Muto Y; Kitano S; Tsutsumida A; Namikawa K; Takahashi A; Nakamura Y; Yamanaka T; Yamamoto N; Yamazaki N
    J Dermatol; 2019 Jun; 46(6):498-506. PubMed ID: 30945333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial.
    Lebbé C; Meyer N; Mortier L; Marquez-Rodas I; Robert C; Rutkowski P; Menzies AM; Eigentler T; Ascierto PA; Smylie M; Schadendorf D; Ajaz M; Svane IM; Gonzalez R; Rollin L; Lord-Bessen J; Saci A; Grigoryeva E; Pigozzo J
    J Clin Oncol; 2019 Apr; 37(11):867-875. PubMed ID: 30811280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy of anti-PD-1 agents in acral and mucosal melanoma.
    Shoushtari AN; Munhoz RR; Kuk D; Ott PA; Johnson DB; Tsai KK; Rapisuwon S; Eroglu Z; Sullivan RJ; Luke JJ; Gangadhar TC; Salama AK; Clark V; Burias C; Puzanov I; Atkins MB; Algazi AP; Ribas A; Wolchok JD; Postow MA
    Cancer; 2016 Nov; 122(21):3354-3362. PubMed ID: 27533633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II multicentre study of plasminogen activator inhibitor-1 inhibitor (TM5614) plus nivolumab for treating anti-programmed cell death 1 antibody-refractory malignant melanoma: TM5614-MM trial.
    Fujimura T; Yoshino K; Kato H; Fukushima S; Ishizuki S; Otsuka A; Matsushita S; Amagai R; Muto Y; Yamazaki E; Kambayashi Y; Yahata T; Miyata T; Fujisawa Y; Asano Y
    Br J Dermatol; 2024 Oct; 191(5):691-697. PubMed ID: 38833158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of PD-1-based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma.
    Kreft S; Gesierich A; Eigentler T; Franklin C; Valpione S; Ugurel S; Utikal J; Haferkamp S; Blank C; Larkin J; Garbe C; Schadendorf D; Lorigan P; Schilling B
    Eur J Cancer; 2019 Jul; 116():207-215. PubMed ID: 31212163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes after progression of disease with anti-PD-1/PD-L1 therapy for patients with advanced melanoma.
    Patrinely JR; Baker LX; Davis EJ; Song H; Ye F; Johnson DB
    Cancer; 2020 Aug; 126(15):3448-3455. PubMed ID: 32463489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world efficacy and toxicity of combined nivolumab and ipilimumab in patients with metastatic melanoma.
    Parakh S; Randhawa M; Nguyen B; Warburton L; Hussain MA; Cebon J; Millward M; Yip D; Ali S
    Asia Pac J Clin Oncol; 2019 Feb; 15(1):26-30. PubMed ID: 30426665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy.
    Gide TN; Quek C; Menzies AM; Tasker AT; Shang P; Holst J; Madore J; Lim SY; Velickovic R; Wongchenko M; Yan Y; Lo S; Carlino MS; Guminski A; Saw RPM; Pang A; McGuire HM; Palendira U; Thompson JF; Rizos H; Silva IPD; Batten M; Scolyer RA; Long GV; Wilmott JS
    Cancer Cell; 2019 Feb; 35(2):238-255.e6. PubMed ID: 30753825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders.
    Brown LJ; Weppler A; Bhave P; Allayous C; Patrinely JR; Ott P; Sandhu S; Haydon A; Lebbe C; Johnson DB; Long GV; Menzies AA; Carlino MS
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic review and meta-analysis efficacy and safety of immune checkpoint inhibitors in advanced melanoma patients with anti-PD-1 progression: a systematic review and meta-analysis.
    Alrabadi NN; Abushukair HM; Ababneh OE; Syaj SS; Al-Horani SS; Qarqash AA; Darabseh OA; Al-Sous MM; Al-Aomar SR; Ahmed YB; Haddad R; Al Qarqaz FA
    Clin Transl Oncol; 2021 Sep; 23(9):1885-1904. PubMed ID: 33877531
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies.
    Algazi AP; Tsai KK; Shoushtari AN; Munhoz RR; Eroglu Z; Piulats JM; Ott PA; Johnson DB; Hwang J; Daud AI; Sosman JA; Carvajal RD; Chmielowski B; Postow MA; Weber JS; Sullivan RJ
    Cancer; 2016 Nov; 122(21):3344-3353. PubMed ID: 27533448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.